Phase 3 N=90 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival（OS） — 10.9; 8.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=22 Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
Hemophilia A
Primary: Change From Baseline in FVIII Activity as Measured by Chromogenic Substrate Assay at Week 52. — 15.13 IU /dL — p=0.0057
Phase 3 N=1,029 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
Respiratory Syncytial Virus Infections
Primary: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 5876.3; 6935.3 Titers
Phase 3 N=1,606 Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) — -1.5; -1.9; -2.1 Percentage point of HbA1c — p=0.0006
Phase 3 N=335 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) — 3.7…
Phase 3 N=22 MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Cytomegalovirus Infection · Cytomegalovirus Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 90.9 Percentage of Participants
Phase 3 N=935 Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
COVID-19
Primary: Time to Sustained Clinical Recovery — 13.3; 12.4 days — p=0.8786
Phase 3 N=1,187 The Prevent Severe COVID-19 (PRESECO) Study
Covid19
Primary: Number of Participants With Sustained Clinical Recovery — 425; 475 Participants
Phase 3 N=242 A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 7.1; 5.6; 3.7; 5.6 months — p=0.0098
Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Phase 3 N=485 Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is…
Phase 3 N=227 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change in the MADRS10 Total Score From Baseline to Day 28 — -15.1; -12.9 score on a scale
Phase 3 N=232 A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change in the MADRS10 Total Score From Baseline to Day 28 — -14.8; -13.9 score on a scale
Phase 3 N=12 Pain Medicine for Wound Care Procedures
Wound Care · Pain Intensity · Hyperalgesia
Primary: Pain Intensity — 3.1; 6.8 score on a scale
Phase 3 N=50 A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Primary: Lactate Dehydrogenase (U/L) at Week 26 — 284.20; 249.72 U/L